Development and in vitro Antifungal Evaluation of a Ternary Essential Oil–Based Oral Phytopharmaceutical Formulation Against Candida albicans
Infection and Drug Resistance · 2026-06 · Volume 19 · 1-10
DOI: 10.2147/idr.s605104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Drug Resistance, 2026-06. Verfasst von Katherine Cuenca-León und 3 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Ciencias de la Salud, Carrera de Odontología, Universidad Católica de Cuenca, Cuenca, Ecuador. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
The increasing resistance of Candida albicans to conventional antifungal agents has intensified the search for alternative therapies based on natural metabolites.
Aim
This study aimed to evaluate the phytochemical profile and antifungal activity of a phytopharmaceutical formulation composed of essential oils from Cymbopogon citratus (lemongrass), Coriandrum sativum (coriander), and Origanum vulgare (oregano), obtained by steam distillation from plants collected in the southern region of Ecuador. Methodology: The chemical composition was characterized by gas chromatography coupled with mass spectrometry (GC–MS). A total of 40 compounds were identified, with carvacrol (30.01%), α-citral (12.57%), β-citral (9.55%), linalool (8.47%), (E)-2-decenal (8.38%), and geraniol (2.81%) as the major constituents. Antifungal activity was assessed using the agar diffusion method against C. albicans ATCC 90028, comparing formulations at 2.5%, 5%, 10%, and 25%.
Results
The ternary formulation at 10% in an alcoholic vehicle exhibited the largest inhibition zone (77.89 ± 2.48 mm), significantly surpassing both positive controls, including 0.12% chlorhexidine gluconate (35.13 ± 0.01 mm) and fluconazole (21.63 ± 6.29 mm). The aqueous formulation also demonstrated considerable antifungal activity, although lower than the alcoholic system.
Conclusion
The novel phytopharmaceutical formulation demonstrated notable antifungal activity and may represent a promising natural alternative for oral candidiasis management. Nevertheless, further studies incorporating complementary methodologies, such as minimum inhibitory and fungicidal concentration (MIC/MFC) assays, as well as in vivo and biocompatibility evaluations, would contribute to strengthening the translational potential and clinical applicability of these findings. Keywords: phytopharmaceutical formulation, essential oils, GC–MS, Candida albicans , antifungal formulation
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Facultad de Ciencias de la Salud, Carrera de Odontología, Universidad Católica de Cuenca, Cuenca, Ecuador.
- Research Group: Innovación y Desarrollo Farmacéutico en Odontología, Carrera de Odontología, Jefatura de Investigación e Innovación, Universidad Católica de Cuenca, Cuenca, Ecuador.
- Department of Pharmaceutical Sciences, University of Salamanca, Salamanca, Spain.
- Ecuadorian Network of Women Scientists (REMCI), Catholic University of Cuenca Node, Quito, Ecuador.
ORCID-Profile: Katherine Cuenca-León, Edisson-Mauricio Pacheco-Quito, Miriam Lima-Illescas, Aránzazu Zarzuelo-Castañeda
Zitieren
APA
Cuenca-León, K., Pacheco-Quito, E. M., Lima-Illescas, M., & Zarzuelo-Castañeda, A. (2026). Development and in vitro Antifungal Evaluation of a Ternary Essential Oil–Based Oral Phytopharmaceutical Formulation Against Candida albicans. Infection and Drug Resistance, Volume 19, 1-10. https://doi.org/10.2147/idr.s605104
Vancouver
Cuenca-León K, Pacheco-Quito EM, Lima-Illescas M, Zarzuelo-Castañeda A. Development and in vitro Antifungal Evaluation of a Ternary Essential Oil–Based Oral Phytopharmaceutical Formulation Against Candida albicans. Infection and Drug Resistance. 2026;Volume 19:1-10. doi:10.2147/idr.s605104
BibTeX
@article{CuencaLen2026,
author = {Cuenca-León, Katherine and Pacheco-Quito, Edisson-Mauricio and Lima-Illescas, Miriam and Zarzuelo-Castañeda, Aránzazu},
title = {Development and in vitro Antifungal Evaluation of a Ternary Essential Oil–Based Oral Phytopharmaceutical Formulation Against Candida albicans},
journal = {Infection and Drug Resistance},
year = {2026},
volume = {Volume 19},
pages = {1--10},
doi = {10.2147/idr.s605104}
}
EUVIMED